Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

1.7K
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.7K
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

1.3K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.3K
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

1.9K
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
1.9K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

2.3K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
2.3K
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

1.6K
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
1.6K
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

1.9K
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
1.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Variability on the energy properties of charcoal and charcoal briquettes for barbecue.

Heliyon·2022
Same author

A case of onychomadesis associated with chilblain-like lesions after COVID-19 infection.

Journal of the European Academy of Dermatology and Venereology : JEADV·2022
Same author

The riddle of PHACE syndrome.

Journal of the European Academy of Dermatology and Venereology : JEADV·2022
Same author

Treatment of children from 6 to 11 years old affected by moderate-severe atopic dermatitis with dupilumab: a first perspective from a single-center real-life experience in Italy.

Journal of the European Academy of Dermatology and Venereology : JEADV·2022
Same author

Effective energy exploitation from horse manure combustion.

Waste management (New York, N.Y.)·2021
Same author

A single-centre real-life experience on effectiveness and safety of dupilumab in adolescents with severe atopic dermatitis in treatment with cyclosporine A.

Journal of the European Academy of Dermatology and Venereology : JEADV·2021
Same journal

Correction to: Autoinflammatory diseases: why they should matter to the dermatologist.

Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia·2021
Same journal

Correction to: Actinic keratoses: when and how to treat a single lesion.

Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia·2021
Same journal

Correction to: Thick melanoma in Tuscany.

Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia·2021
Same journal

Spastic quadriplegia following intradermal use of hydrogen peroxide in the tardive curettage procedure for the treatment of a giant congenital nevus.

Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia·2021
Same journal

Genetic mutations in primary malignant melanoma of the esophagus: case report and literature review.

Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia·2020
Same journal

Cutaneous manifestations in an Italian military COVID hub.

Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia·2020
See all related articles

Related Experiment Video

Updated: Apr 21, 2026

Laparoscopic Anatomical Right Hemihepatectomy via the In Situ Anterior Approach
05:30

Laparoscopic Anatomical Right Hemihepatectomy via the In Situ Anterior Approach

Published on: August 8, 2025

785

Beta-blockers for hemangiomas.

C Gelmetti1, R Cavalli

  • 1Unit of Pediatric Dermatology, Department of Surgical and Transplant Pathophysiology Milano University, Fondazione Ca' Granda "Ospedale Maggiore Policlinico",Milan, Italy - ric.cavalli@tiscali.it.

Giornale Italiano Di Dermatologia E Venereologia : Organo Ufficiale, Societa Italiana Di Dermatologia E Sifilografia
|November 5, 2014
PubMed
Summary
This summary is machine-generated.

Infantile hemangiomas (IHs), common infant tumors, often require treatment despite natural regression. Oral propranolol is now the preferred therapy due to its high efficacy and safety profile.

More Related Videos

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
07:10

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

22.9K
A Patient-Derived Xenograft Model for Venous Malformation
06:51

A Patient-Derived Xenograft Model for Venous Malformation

Published on: June 15, 2020

4.5K

Related Experiment Videos

Last Updated: Apr 21, 2026

Laparoscopic Anatomical Right Hemihepatectomy via the In Situ Anterior Approach
05:30

Laparoscopic Anatomical Right Hemihepatectomy via the In Situ Anterior Approach

Published on: August 8, 2025

785
Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
07:10

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

22.9K
A Patient-Derived Xenograft Model for Venous Malformation
06:51

A Patient-Derived Xenograft Model for Venous Malformation

Published on: June 15, 2020

4.5K

Area of Science:

  • Pediatric Oncology
  • Dermatology
  • Pharmacology

Background:

  • Infantile hemangiomas (IHs) are the most common tumors in infancy.
  • IHs typically exhibit rapid growth followed by spontaneous involution.
  • Treatment is indicated for IHs with rapid growth, critical locations, complications, or functional impairment.

Purpose of the Study:

  • To review the current therapeutic landscape for infantile hemangiomas.
  • To highlight the role of propranolol in IH management.
  • To discuss the efficacy and safety of propranolol for IHs.

Main Methods:

  • Literature review of infantile hemangioma treatment modalities.
  • Analysis of studies on propranolol's effectiveness in IHs.
  • Comparison of propranolol with historical therapies for IHs.

Main Results:

  • Oral propranolol has become the first-line systemic treatment for IHs since 2008.
  • Propranolol demonstrates nearly 100% efficacy with rapid action and minimal side effects.
  • It has replaced older, riskier treatments like oral steroids and vincristine.

Conclusions:

  • Oral propranolol has revolutionized infantile hemangioma treatment.
  • Its high efficacy and favorable safety profile make it the preferred therapy.
  • Formal approvals by FDA and EMA validate its use in IH management.